CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced that positive data from a Phase 2 trial of romidepsin conducted by the U.S. National Cancer Institute (NCI) were presented at the 13th Congress of the European Hematology Association in Copenhagen, Denmark. Romidepsin is a novel, cyclic peptide, pan-HDAC inhibitor under investigation for hematologic malignancies.
